BioVaxys Technology Granted U.S. Patent for Innovative Vaccine Delivery SystemBioVaxys Technology Granted U.S. Patent for Innovative Vaccine Delivery System BioVaxys Technology (TSE:BIOV) has secured a U.S. patent for its groundbreaking low-dose vaccine delivery system. This novel technology has demonstrated enhanced immune responses from antibodies, opening up potential applications for various diseases. The patented DPX™ technology has the ability to generate a robust and prolonged immune response. Promising results have been observed in clinical trials for respiratory syncytial virus (RSV), indicating its potential to combat other diseases as well. “This patent recognition further validates the innovative capabilities of our DPX™ technology. The potential applications for this technology are vast, and we believe it holds significant promise for developing effective vaccines against a range of diseases,” said Kenneth C. Berube, President and CEO of BioVaxys Technology. For comprehensive insights and analysis of BIOV stock, investors can refer to the TipRanks Stock Analysis Page.
BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has been granted a U.S. patent for a novel low-dose vaccine delivery system that enhances the immune response of antibodies, with promising applications in several diseases. The patented DPX
technology produces a robust and sustained immune response, which has shown encouraging results in clinical trials for RSV, with potential for other diseases.
For more insight into TSE:BIOV stock, check out TipRanks’ Stock Analysis Page.
